Last updated: February 20, 2026
What Is NDC 00713-0883?
NDC 00713-0883 corresponds to Veklury (remdesivir), an antiviral drug approved by the FDA for treatment of hospitalized COVID-19 patients. Remdesivir has been a key component in COVID-19 treatment protocols since its emergency use authorization in May 2020, later gaining full FDA approval in October 2020.
Market Size and Demand Drivers
Current Market Size
- The global antiviral market was valued at approximately $42 billion in 2022.
- The COVID-19 antiviral segment accounts for an estimated $5 billion of that figure; remdesivir dominates this segment.
Demand Trends
-
COVID-19 hospitalizations drive demand for remdesivir. As of 2023, global hospitalization rates fluctuate, with variants influencing case severity.
-
Regulatory approvals expand access:
- FDA full approval (October 2020).
- Emergency Use Authorizations (EUAs) in multiple countries.
-
Competitive landscape:
- Other antiviral drugs like Pfizer’s Paxlovid and Merck’s Lagevrio (molnupiravir) present alternatives with different administration routes and pricing.
Market Penetration
- In the U.S., remdesivir is administered in hospitals; approximately 2 million courses were delivered globally in 2022.
- Usage declines as COVID-19 becomes endemic and vaccination rates increase; however, remdesivir remains a first-line treatment for severe cases.
Supply and Manufacturing Capacity
Key Manufacturers
- Gilead Sciences (original patent holder and sole manufacturer of remdesivir).
- Production capacity increased from 3 million to 10 million doses annually since early 2021.
- Plans for expansion aim to meet global demand, especially in low- and middle-income countries.
Supply Chain Dynamics
- U.S. government previously purchased large stockpiles.
- Ongoing supply relies on Gilead’s manufacturing and licensing agreements with generic producers in various regions.
Pricing Analysis
Current Pricing Structure
- List price per treatment course (healthcare provider): $3,120 in the U.S. (as of 2022).
- Actual transaction prices are often negotiated downward, especially via government contracts and insurance rebates.
Price Variability
| Region |
Approximate Treatment Cost |
Notes |
| United States |
$3,120 |
List price; discounts available through negotiations |
| Europe |
$2,500–$3,000 |
Variations depending on country and payer |
| Low-income countries |
$0–$1,200 |
Through Gilead licensing agreements |
Pricing Trends
- Pricing has stabilized since initial rollout.
- No significant reductions expected while demand remains high in COVID-19 management.
- Future price declines may occur if alternative therapies gain prominence or patents expire.
Patent Landscape and Generic Competition
- Gilead holds patents until 2029 in key markets.
- License agreements with generics in India, Egypt, and other jurisdictions allow for lower-cost production.
- Patent expiry in key markets could lead to generic versions, decreasing prices by 50–70%.
Regulatory and Policy Impact
- Governments and health agencies influence pricing through negotiations and procurement contracts.
- Pricing pressure may increase as patents expire and generics enter the market.
- Strategic stockpiling and stock levels influence demand and pricing stability.
Price Projections (2023-2028)
| Year |
Estimated Price per Course |
Influencing Factors |
| 2023 |
$3,000–$3,200 |
Stable demand, limited competition |
| 2024 |
$2,800–$3,000 |
Emerging competition, patent protections |
| 2025 |
$2,500–$2,800 |
Patent expiration in some regions; increased generics |
| 2026 |
$2,000–$2,500 |
Expanded generics, greater international access |
| 2027 |
$1,800–$2,200 |
Increased competition, supply chain stabilization |
| 2028 |
$1,500–$2,000 |
Broader generic availability, policy-driven discounts |
Risks and Opportunities
Risks
- Patent expiration and patent challenges.
- Emergence of more effective or cheaper treatments.
- Regulatory restrictions or supply disruptions.
Opportunities
- Increased utilization in low-income countries via licensing.
- Expansion into new indications or additional viral diseases.
- Cost reductions through patent litigation outcomes or patent expiries.
Key Takeaways
- The remdesivir market remains substantial amid COVID-19 treatment needs.
- Price stability persists in the short term, with future declines likely post-patent expiration.
- Supply capacity is on an upward trajectory, supporting broader access.
- Competitive threats from alternative antivirals could influence pricing and market share.
- Gilead maintains a dominant position with ongoing patent protections.
FAQs
Q1: How does remdesivir compare in price to other COVID-19 antivirals?
Remdesivir’s list price of around $3,120 per course exceeds Paxlovid’s approximate $700 but is comparable to Lagevrio.
Q2: What factors most influence future price declines?
Patent expirations, generic manufacturing, and increased competition will primarily drive prices downward.
Q3: Are there regional differences in remdesivir access and pricing?
Yes. Developed countries often pay higher list prices, while licensing agreements and subsidies lower costs in developing nations.
Q4: Can Gilead extend its patent protections?
Potentially, through patent extensions, patent litigation, or new formulations, delaying generic entry.
Q5: What is the outlook for remdesivir outside COVID-19?
Research into remdesivir’s efficacy against other viral illnesses remains limited. Its main application continues to be COVID-19 treatment.
References
[1] Gilead Sciences. (2022). Remdesivir (Veklury) prescribing information.
[2] IQVIA. (2022). Global antiviral market report.
[3] U.S. Food and Drug Administration. (2020). FDA approval of Veklury.
[4] World Health Organization. (2023). COVID-19 pandemic data and treatment guidelines.
[5] Statista. (2023). COVID-19 antiviral drug market revenue projections.
